Published in

Bentham Science Publishers, Current Topics in Medicinal Chemistry, 3(20), p. 227-243, 2020

DOI: 10.2174/1568026620666200124094949

Links

Tools

Export citation

Search in Google Scholar

Phenylamino-pyrimidine (PAP) Privileged Structure: Synthesis and Medicinal Applications

Journal article published in 2020 by Luiz Claudio Ferreira Pimentel ORCID, Anna Claudia Cunha ORCID, Lucas Villas Boas Hoelz ORCID, Henayle Fernandes Canzian ORCID, Debora Inacio Leite Firmino Marinho ORCID, Nubia Boechat ORCID, Monica Macedo Bastos ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The phenylamino-pyrimidine (PAP) nucleus has been demonstrated to be useful for the development of new drugs and is present in a wide variety of antiretroviral agents and tyrosine kinase inhibitors (TKIs). This review aims to evaluate the application of PAP derivatives in drugs and other bioactive compounds. It was concluded that PAP derivatives are still worth exploring, as they may provide highly competitive ATP TKI’s with nano/picomolar activity.